Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 19, 2018 - Issue 18
Submit an article Journal homepage
1,095
Views
31
CrossRef citations to date
0
Altmetric
Drug Evaluation

Ozanimod for the treatment of relapsing remitting multiple sclerosis

Ludwig RascheNeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität, and Berlin Institute of Health, Berlin, GermanyView further author information
&
Friedemann PaulNeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität, and Berlin Institute of Health, Berlin, Germany;Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität, and Berlin Institute of Health, Berlin, Germany;Department of Neurology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyCorrespondence[email protected]
View further author information
Pages 2073-2086 | Received 16 Jul 2018, Accepted 22 Oct 2018, Published online: 08 Nov 2018

Citations (31)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Laura Dumitrescu, Athanasios Papathanasiou, Catalina Coclitu, Afagh Garjani, Nikos Evangelou, Cris S. Constantinescu, Bogdan Ovidiu Popescu & Radu Tanasescu. (2023) An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis. Expert Opinion on Pharmacotherapy 24:4, pages 495-509.
Read now
Victor Constantinescu, Katja Akgün & Tjalf Ziemssen. (2022) Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more. Expert Opinion on Drug Metabolism & Toxicology 18:10, pages 675-693.
Read now
Stefan Biendl, Cécile Häberli & Jennifer Keiser. (2022) Discovery of novel antischistosomal scaffolds from the open access Pandemic Response Box. Expert Review of Anti-infective Therapy 20:4, pages 621-629.
Read now
Marzia Fronza, Lorena Lorefice, Jessica Frau & Eleonora Cocco. (2021) An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis. Drug Design, Development and Therapy 15, pages 1993-2004.
Read now

Articles from other publishers (27)

Dnyandev G. Gadhave, Vrashabh V. Sugandhi & Chandrakant R. Kokare. (2024) Potential biomaterials and experimental animal models for inventing new drug delivery approaches in the neurodegenerative disorder: Multiple sclerosis. Brain Research 1822, pages 148674.
Crossref
Moein Amin & Carrie M Hersh. (2023) Updates and advances in multiple sclerosis neurotherapeutics. Neurodegenerative Disease Management 13:1, pages 47-70.
Crossref
Lin Yang, Kaiyue Zhang, Meng Xu, Youyu Xie, Xiangqi Meng, Hualei Wang & Dongzhi Wei. (2022) Mechanism‐Guided Computational Design of ω‐Transaminase by Reprograming of High‐Energy‐Barrier Steps. Angewandte Chemie International Edition 61:52.
Crossref
Lin Yang, Kaiyue Zhang, Meng Xu, Youyu Xie, Xiangqi Meng, Hualei Wang & Dongzhi Wei. (2022) Mechanism‐Guided Computational Design of ω‐Transaminase by Reprograming of High‐Energy‐Barrier Steps. Angewandte Chemie 134:52.
Crossref
Lifan Xu, Peng Lu & Yubin Wang. (2022) Sphingosine 1-phosphate receptor modulators for the treatment of inflammatory bowel disease and other immune-mediated diseases. Medicinal Chemistry Research 31:12, pages 2074-2088.
Crossref
Hussein Baharlooi, Amir Hossein Mansourabadi, Moein Minbashi Moeini, Leila Mohamed Khosroshahi & Maryam Azimi. (2021) Nucleic Acids as Novel Therapeutic Modalities to Address Multiple Sclerosis Onset and Progression. Cellular and Molecular Neurobiology 42:8, pages 2611-2627.
Crossref
Zeinab Jan, Samaneh Mollazadeh, Khalil Abnous, Seyed Mohammad Taghdisi, Abolghasem Danesh, Mohammad Ramezani & Mona Alibolandi. (2022) Targeted Delivery Platforms for the Treatment of Multiple Sclerosis. Molecular Pharmaceutics 19:7, pages 1952-1976.
Crossref
SOUMYADIP GHOSH, DEBGOPAL GANGULY & SUBHABROTA MAJUMDER. (2022) A REVIEW ON PHARMACOLOGICAL AND THERAPEUTIC INSIGHT OF OZANIMOD FOR COLON DISEASE IN NANO-STRUCTURE. International Journal of Pharmacy and Pharmaceutical Sciences, pages 13-19.
Crossref
Jie Wang, Idan Goren, Bo Yang, Sinan Lin, Jiannan Li, Michael Elias, Claudio Fiocchi & Florian Rieder. (2021) Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis ‐ a unique therapeutic target in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 55:3, pages 277-291.
Crossref
Victor Constantinescu, Rocco Haase, Katja Akgün & Tjalf Ziemssen. (2022) S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review. Therapeutic Advances in Neurological Disorders 15, pages 175628642211331.
Crossref
Kerri A. Schoedel, Carine Kolly, Anne Gardin, Srikanth Neelakantham & Kasra Shakeri-Nejad. (2021) Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data. Psychopharmacology 239:1, pages 1-13.
Crossref
Roland Seifert & Friedemann Paul. 2022. Arzneiverordnungs-Report 2022. Arzneiverordnungs-Report 2022 497 517 .
Stanley Cohan, Tom Tencer, Stella Arndorfer, Xuelian Zhu, Marko Zivkovic & Jinender Kumar. (2021) Matching-adjusted indirect treatment comparison of ozanimod versus teriflunomide for relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders 52, pages 102972.
Crossref
Stanley Cohan, Jinender Kumar, Stella Arndorfer, Xuelian Zhu, Marko Zivkovic & Tom Tencer. (2021) Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison. CNS Drugs 35:7, pages 795-804.
Crossref
Andrea M Kuczynski & Jiwon Oh. (2021) Ozanimod for the treatment of relapsing forms of multiple sclerosis. Neurodegenerative Disease Management 11:3, pages 207-220.
Crossref
Jingyi Tong, Qin Zou, Yongmin Chen, Xiaoping Liao, Rong Chen, Lin Ma, Daqi Zhang & Qifu Li. (2021) Efficacy and acceptability of the S1P receptor in the treatment of multiple sclerosis: a meta-analysis. Neurological Sciences 42:5, pages 1687-1695.
Crossref
Donald J. AbrahamWilliam J. Pitts & Alaric J. Dyckman. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery 1 43 .
Jian Zhang, Shengliang Shi, Yueling Zhang, Jiefeng Luo, Jian Tang & Jinglian Luo. (2021) Ozanimod for relapsing-remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2022:4.
Crossref
Jerold Chun, Gavin Giovannoni & Samuel F. Hunter. (2020) Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects. Drugs 81:2, pages 207-231.
Crossref
Anna N. Belova, Gennadij E. Sheiko & Evgeniya M. Belova. (2021) Multiple sclerosis-modifying therapies: view in the future. Neurology Bulletin LII:3, pages 41-54.
Crossref
Georges Jalkh, Rachelle Abi Nahed, Gabrielle Macaron & Mary Rensel. (2020) Safety of Newer Disease Modifying Therapies in Multiple Sclerosis. Vaccines 9:1, pages 12.
Crossref
Grace Lassiter, Carlie Melancon, Tyler Rooney, Anne-Marie Murat, Jessica S. Kaye, Adam M. Kaye, Rachel J. Kaye, Elyse M. Cornett, Alan D. Kaye, Rutvij J. Shah, Omar Viswanath & Ivan Urits. (2020) Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects. Neurology International 12:3, pages 89-108.
Crossref
Bergithe E. Oftedal & Anette S. B. Wolff. (2020) New era of therapy for endocrine autoimmune disorders. Scandinavian Journal of Immunology 92:5.
Crossref
Elyse Swallow, Oscar Patterson-Lomba, Lei Yin, Rina Mehta, Corey Pelletier, David Kao, James K Sheffield, Tim Stonehouse & James Signorovitch. (2020) Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis. Journal of Comparative Effectiveness Research 9:4, pages 275-285.
Crossref
Régis Bordet, William Camu, Jérôme De Seze, David-Axel Laplaud, Jean-Christophe Ouallet & Eric Thouvenot. (2020) Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement. Revue Neurologique 176:1-2, pages 100-112.
Crossref
Rui Pedro Moura & Bruno Sarmento. (2019) Therapeutic Approaches toward Multiple Sclerosis: Where Do We Stand and Where Are We Headed?. Advanced Therapeutics 2:10, pages 1900070.
Crossref
Friedemann Paul. 2019. Flammer Syndrome. Flammer Syndrome 145 163 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.